# Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

> **NCT06357533** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 675 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Datopotamab Deruxtecan
- **DRUG:** Rilvegostomig
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06357533
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-11
- **Primary completion:** 2029-12-28
- **Final completion:** 2029-12-28
- **Target enrollment:** 675 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06357533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06357533, "Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06357533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*